Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Notes Payables (2017 - 2025)

Regen BioPharma (RGBPP) has disclosed Notes Payables for 10 consecutive years, with $968014.0 as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables rose 800.42% to $968014.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $968014.0, a 800.42% increase, with the full-year FY2025 number at $1.0 million, up 107.3% from a year prior.
  • Notes Payables was $968014.0 for Q4 2025 at Regen BioPharma, down from $1.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.0 million in Q3 2025 to a low of $1000.0 in Q1 2021.
  • A 5-year average of $154474.7 and a median of $1000.0 in 2021 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: changed 0.0% in 2021, then surged 49888.0% in 2024.
  • Regen BioPharma's Notes Payables stood at $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then soared by 10650.7% to $107507.0 in 2024, then surged by 800.42% to $968014.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Notes Payables are $968014.0 (Q4 2025), $1.0 million (Q3 2025), and $100000.0 (Q2 2025).